NewsWatch: Moderna’s COVID-19 vaccine candidate sparks market rally after achieving 94.5% efficacy in late-stage trial and requires only standard refrigeration

MARKETWATCH FRONT PAGE

Moderna Inc. said Monday its COVID-19 vaccine candidate met its primary endpoint in a Phase 3 trial, demonstrating 94.5% efficacy, a far higher benchmark than originally expected, sparking a broad-based market rally. See full story.

Dow futures jump nearly 500 points as investors cheer Moderna vaccine progress

Stock-index futures rise sharply Monday, with equities set to build on strong gains inspired last week by progress toward a COVID-19 vaccine as investors look past a continued surge in new cases of the disease and the lack of progress toward another round of aid for strapped consumers. See full story.

Could the Fed act early? Yes, says this strategist who maps out the central bank’s possible next move

The Federal Reserve might not wait until its regularly scheduled meeting to take further action. See full story.

Walmart earnings preview: As many as 19 million households may already be Walmart+ members

Walmart has added pet services and sold off its Argentina business in recent days See full story.

These are the 14 value stocks that top-performing investment newsletters like the most

Many of the newsletter editors think value is finally reasserting its historical dominance over growth. See full story.

MARKETWATCH PERSONAL FINANCE

‘Five years ago, she and her sister inherited a substantial amount of money (equally split between them). Think low six figures.’ See full story.

Let's block ads! (Why?)

November 17, 2020 at 03:00AM

http://www.marketwatch.com/news/story.asp?guid=%7B4FC8EC62-99D1-43C4-8EC3-D182460295AB%7D&siteid=rss&rss=1